

December 1, 2022

Company: Chiome Bioscience Inc.

Representative: Shigeru Kobayashi, President & CEO

(Code: 4583, Tokyo Stock Exchange Growth)

**Research Presentation of the ADLib® System
in the 45th Annual Meeting of the Molecular Biology Society of Japan**

Chiome Bioscience Inc. presents our research on examining of affinity maturation step in human ADLib® system in the 45th annual meeting of the Molecular Biology Society of Japan held at Makuhari Messe from November 30 to December 2, 2022.

The human ADLib® system can simultaneously achieve antibody production and affinity maturation. The antibody obtained from human ADLib® can be seamlessly affinity-matured resulting in high-affinity human antibodies in a one-stop order. Here, we demonstrated even mammalian antibodies derived from non-ADLib® system could be effectively affinity matured in this system.

These results show a great potential of the human ADLib® system to generate human antibodies with high affinity for therapeutic targets effectively, which will accelerate drug discovery research and contract research business.

Detailed information of this presentation

The presentation number: 3P-329

Date and Time: December 2 between 13:45 and 14:45

Title: Fast-tracking antibody affinity maturation using a chicken B cell-based display system,
ADLib® KI-AMP

Presentation Style: Poster Session

The 45th Annual Meeting of the Molecular Biology Society of Japan (website)

https://www2.aeplan.co.jp/mbsj2022/science_pitch.html

<About ADLib® system technology>

The ADLib® system offers a platform with unique antibody libraries that utilizes the antibody diversification mechanism of chicken B cell. It is a rapid one-stop order drug discovery and research tool that can complete all the steps necessary for antibody drug discovery such as selection, full-length IgG expression, humanization, and affinity maturation on one in vitro platform.

【Inquiries】

Chiome Bioscience Inc. Investor Relations

E-mail: ir@chiome.co.jp